AUTOLOGOUS CD133+ BONE MARROW-DERIVED STEM CELL THERAPY FOR MODERATE-TO-SEVERE ASHERMAN SYNDROME: RESULTS FROM A PHASE 1/2 CLINICAL TRIAL

Authors
Category Primary study
ConferenceASRM 2025 Global Collaboration to Advance Reproductive Health
Year 2025
This article has no abstract
Epistemonikos ID: 10956d1c1d7406a336b4a035c601fea0aa1b2089
First added on: Dec 19, 2025